New treatment options for bronchiectasis

Therapeutic Advances in Respiratory Disease

Volumn 4, Issue 2, 2010, Pages 93-99

  Metersky, Mark L ^a  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

antibacterial agents; bronchiectasis; macrolides; Pseudomonas aeruginosa; therapeutics

Indexed keywords

AMIKACIN; AZITHROMYCIN; AZTREONAM; CIPROFLOXACIN; CLARITHROMYCIN; COLISTIN; CORTICOSTEROID; ERDOSTEINE; ERYTHROMYCIN; FOSFOMYCIN; LIPOSOME; MACROLIDE; MANNITOL; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TERBUTALINE; TOBRAMYCIN;

ABSENCE OF SIDE EFFECTS; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BREATHING EXERCISE; BREATHING PATTERN; BRONCHIECTASIS; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; CLINICAL TRIAL; CYSTIC FIBROSIS; DIFFUSE PANBRONCHIOLITIS; DISEASE EXACERBATION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRY POWDER; DYSPNEA; EXPIRATORY FLOW RATE; HUMAN; LOW DRUG DOSE; LUNG DISEASE; LUNG FUNCTION; MINIMUM INHIBITORY CONCENTRATION; MULTIPLE CYCLE TREATMENT; NEBULIZATION; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY AIRFLOW; REVIEW; SINGLE DRUG DOSE; THORAX PAIN; TREATMENT OUTCOME; WHEEZING;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS; BRONCHIAL SPASM; BRONCHIECTASIS; HUMANS; MACROLIDES; MANNITOL; SALINE SOLUTION, HYPERTONIC;

EID: 77951894250     PISSN: 17534658     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753465810366858     Document Type: Review

References (34)

1. Angrill, J., Agusti, C., de Celis, R., Rano, A., Gonzalez, J., Sole, T. et al. (2002) Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax 57: 15-19.
2. Anwar, G.A., Bourke, S.C., Afolabi, G., Middleton, P., Ward, C. and Rutherford, R.M. ( 2008) Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med 102: 1494-1496.
3. Barker, A.F. ( 2002) Bronchiectasis. N Engl J Med 346: 1383-1393.
4. Barker, A.F., Couch, L., Fiel, S.B., Gotfried, M.H., Ilowite, J., Meyer, K.C. et al. (2000) Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 162: 481-485.
5. Bilton, D., Bruinenberg, P., Otulana, B., Morishige, R. and Blanchard, J. ( 2009a) Inhaled liposomal ciprofloxacin hydrochloride significantly reduces sputum pseudomonas aeruginosa density in CF and non-CF bronchiectasis. Am J Respir Crit Care Med 179: A3214.
6. Bilton, D., Daviskas, E., Jaques, A., Anderson, S.D. and Charlton, B. ( 2009b) A randomised, placebo-controlled trial of inhaled mannitol in patients with bronchiectasis. Am J Respir Crit Care Med 179: A3221.
7. Bilton, D., Henig, N., Morrissey, B. and Gotfried, M. ( 2006) Addition of inhaled tobramycin to ciprofloxacin for acute exacerbations of Pseudomonas aeruginosa infection in adult bronchiectasis. Chest 130: 1503-1510.
8. Courtney, J.M., Kelly, M.G., Watt, A., Garske, L., Bradley, J., Ennis, M. et al. (2008) Quality of life and inflammation in exacerbations of bronchiectasis. Chron Respir Dis 5: 161-168.
9. Crisafulli, E., Coletti, O., Costi, S., Zanasi, E., Lorenzi, C., Lucic, S. et al. (2007) Effectiveness of erdosteine in elderly patients with bronchiectasis and hypersecretion: a 15-day, prospective, parallel, open-label, pilot study. Clin Ther 29: 2001-2009.
10. Davies, G. and Wilson, R. ( 2004) Prophylactic antibiotic treatment of bronchiectasis with azithromycin. Thorax 59: 540-541.
11. Daviskas, E., Anderson, S.D., Eberl, S., Chan, H.K. and Bautovich, G. ( 1999) Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis. Am J Respir Crit Care Med 159: 1843-1848.
12. Daviskas, E., Anderson, S.D., Eberl, S., Chan, H.K. and Young, I.H. ( 2001) The 24-h effect of mannitol on the clearance of mucus in patients with bronchiectasis. Chest 119: 414-421.
13. Daviskas, E., Anderson, S.D., Gomes, K., Briffa, P., Cochrane, B., Chan, H.K. et al. (2005) Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology 10: 46-56.
14. Donaldson, S.H., Bennett, W.D., Zeman, K.L., Knowles, M.R., Tarran, R. and Boucher, R.C. ( 2006) Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 354: 241-250.
15. Drobnic, M.E., Sune, P., Montoro, J.B., Ferrer, A. and Orriols, R. ( 2005) Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother 39: 39-44.
16. Elkins, M.R., Robinson, M., Rose, B.R., Harbour, C., Moriarty, C.P., Marks, G.B. et al. (2006) A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354: 229-240.
17. Griffith, D.E., Aksamit, T., Brown-Elliott, B.A., Catanzaro, A., Daley, C., Gordin, F. et al. (2007) An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175: 367-416.
18. Ilowite, J., Spiegler, P. and Chawla, S. ( 2008) Bronchiectasis: new findings in the pathogenesis and treatment of this disease. Curr Opin Infect Dis 21: 163-167.
19. Kellett, F., Redfern, J. and Niven, R.M. ( 2005) Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Respir Med 99: 27-31.
20. Kudoh, S., Azuma, A., Yamamoto, M., Izumi, T. and Ando, M. ( 1998) Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 157: 1829-1832.
21. MacLeod, D.L., Barker, L.M., Sutherland, J.L., Moss, S.C., Gurgel, J.L., Kenney, T.F. et al. (2009) Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis. J Antimicrob Chemother 64: 829-836.
22. McCoy, K.S., Quittner, A.L., Oermann, C.M., Gibson, R.L., Retsch-Bogart, G.Z. and Montgomery, A.B. ( 2008) Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 178: 921-928.
23. O–Donnell, A.E. ( 2008) Bronchiectasis. Chest 134: 815-823.
24. O–Donnell, A.E., Barker, A.F., Ilowite, J.S. and Fick, R.B. ( 1998) Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. Chest 113: 1329-1334.
25. O–Donnell, A.E., Swarnakar, R., Yahina, L., Nikolova, P., MArinov, R., Waghray, P. et al. (2009) A placebo-controlled study of liposomal amikacin for inhalation nebulized once daily in the treatment of bronchiectatic patients with chronic Pseudomonas aeruginosa lung infection. Eur Respir J 34: 231S.
26. Ramsey, B.W., Pepe, M.S., Quan, J.M., Otto, K.L., Montgomery, A.B., Williams-Warren, J. et al. (1999) Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 340: 23-30.
27. Scheinberg, P. and Shore, E. ( 2005) A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 127: 1420-1426.
28. Shinkai, M., Henke, M.O. and Rubin, B.K. ( 2008) Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther 117: 393-405.
29. Steinfort, D.P. and Steinfort, C. ( 2007) Effect of long-term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J 37: 495-498.
30. Tsang, K.W., Ho, P.I., Chan, K.N., Ip, M.S., Lam, W.K., Ho, C.S. et al. (1999) A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 13: 361-364.
31. Tsang, K.W. and Tipoe, G.L. ( 2004) Bronchiectasis: not an orphan disease in the East. Int J Tuberc Lung Dis 8: 691-702.
32. Weycker, D., Edelsberg, J., Oster, G. and Tino, G. ( 2005) Prevalence and economic burden of bronchiectasis. Clin Pulm Med 12: 205-209.
33. Wills, P. and Greenstone, M. ( 2001) Inhaled hyperosmolar agents for bronchiectasis. Cochrane Database Syst Rev 2: CD002996.
34. Yalcin, E., Kiper, N., Ozcelik, U., Dogru, D., Firat, P., Sahin, A. et al. (2006) Effects of claritromycin on inflammatory parameters and clinical conditions in children with bronchiectasis. J Clin Pharm Ther 31: 49-55.